Muhammad Uzair Saqlain, MD
Medical Oncology · Elkhart, INNPI 1730494915
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,599 of the $2,003 with a category attached, or 79.8%. It is spread thinly across 37 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $759 and has fallen 81.2% since, to $143 in 2025. That places this record below the midpoint for medical oncology clinicians in IN, where the typical reported total is $2,472.
Across 78 payments — averaging $25.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$285
- AstraZeneca$157
- E.r. Squibb & Sons, L.L.C.$157
- Genentech USA, Inc.$148
- Incyte Corporation$123
- Novartis$117
- plus $1K from 31 others
What the payments were for
- Food & beverage$1,59980%
- Education$40420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $285 |
| AstraZeneca | 7 | $157 |
| E.r. Squibb & Sons, L.L.C. | 6 | $157 |
| Genentech USA, Inc. | 5 | $148 |
| Incyte Corporation | 2 | $123 |
| Novartis | 5 | $117 |
| Pfizer | 6 | $110 |
| Gilead(2 entities) | 2 | $79 |
| Regeneron Healthcare Solutions, Inc. | 4 | $67 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $56 |
| GSK | 2 | $48 |
| Sirtex Medical Inc | 1 | $45 |
| Bristol Myers Squibb | 2 | $42 |
| Stryker | 1 | $41 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Merck | 2 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Adaptive Biotechnologies Corporation | 1 | $30 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Beigene USA, Inc. | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Exelixis Inc. | 1 | $21 |
| Acrotech Biopharma Inc. | 1 | $21 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| Seagen Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Sobi, Inc | 1 | $16 |
| EMD Serono, Inc. | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $14 |
How this compares
$2,003 in reported general payments places this provider in the 45th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 18 | $262,707 |
| BrukinsaZanubrutinib | 16 | $240,969 |
| ImbruvicaIbrutinib | 15 | $239,852 |
| NubeqaDarolutamide | 12 | $164,214 |
| VenclextaVenetoclax | 13 | $54,135 |
| Abiraterone Acetate | 81 | $24,569 |
| EliquisApixaban | 21 | $18,727 |
| Dexamethasone | 107 | $1,436 |
| Ondansetron Hcl | 97 | $1,034 |
| Prochlorperazine Maleate | 83 | $905 |
| Letrozole | 43 | $831 |
| Imatinib Mesylate | 12 | $692 |
| Anastrozole | 66 | $664 |
| Hydroxyurea | 23 | $541 |
| Potassium Chloride | 22 | $493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $28 | $240,96916 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $56 | $239,85215 claims |
| BayerNubeqa | $18 | $164,21412 claims |
| AbbVieVenclexta | $18 | $54,13513 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $30 | $24,56981 claims |
| PfizerEliquis | $110 | $18,72721 claims |
| Lilly USA, LLCOlanzapine | $32 | $32736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Elkhart
- Hafiz AslamElkhart$909
- Costantine AlbanyLafayette$212K
- Sunil BabuFort Wayne$166K
- Natraj AmmakkanavarIndianapolis$129K
- Rafat AnsariMishawaka$90K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Eduardo BraunWestville$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.